pI: 7.9104 |
Length (AA): 358 |
MW (Da): 40663 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_130000)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_57135 | Phosphatidylinositol-specific phospholipase C, X domain containing protein |
Brugia malayi | Bm1_36730 | MGC53544 protein |
Caenorhabditis elegans | CELE_F38E9.1 | Protein F38E9.1 |
Dictyostelium discoideum | DDB_G0267488 | hypothetical protein |
Dictyostelium discoideum | DDB_G0293730 | TIM beta/alpha-barrel domain-containing protein |
Dictyostelium discoideum | DDB_G0269228 | phosphatidylinositol-specific phospholipase C X domain-containing protein |
Drosophila melanogaster | Dmel_CG10747 | CG10747 gene product from transcript CG10747-RB |
Echinococcus granulosus | EgrG_000999500 | PLC phosphodiesterase TIM beta alpha barrel domain |
Echinococcus granulosus | EgrG_001071600 | Phospholipase C |
Entamoeba histolytica | EHI_012410 | hypothetical protein |
Entamoeba histolytica | EHI_049280 | hypothetical protein |
Entamoeba histolytica | EHI_103490 | hypothetical protein, conserved |
Echinococcus multilocularis | EmuJ_000999500 | PLC phosphodiesterase, TIM beta alpha barrel domain |
Echinococcus multilocularis | EmuJ_001071600 | Phospholipase C |
Homo sapiens | ENSG00000240891 | phosphatidylinositol-specific phospholipase C, X domain containing 2 |
Homo sapiens | ENSG00000182836 | phosphatidylinositol-specific phospholipase C, X domain containing 3 |
Loa Loa (eye worm) | LOAG_14342 | phosphatidylinositol-specific phospholipase C |
Loa Loa (eye worm) | LOAG_05941 | hypothetical protein |
Mus musculus | ENSMUSG00000049148 | phosphatidylinositol-specific phospholipase C, X domain containing 3 |
Mus musculus | ENSMUSG00000087141 | phosphatidylinositol-specific phospholipase C, X domain containing 2 |
Onchocerca volvulus | OVOC9286 |
|
Schistosoma japonicum | Sjp_0026320 | ko:K01114 phospholipase C [EC3.1.4.3], putative |
Schistosoma mansoni | Smp_018360 | hypothetical protein |
Schmidtea mediterranea | mk4.029690.00 | |
Schmidtea mediterranea | mk4.000258.07 | |
Schmidtea mediterranea | mk4.004696.00 | |
Schmidtea mediterranea | mk4.001510.02 | |
Schmidtea mediterranea | mk4.000819.02 | |
Schmidtea mediterranea | mk4.001510.03 | |
Trypanosoma brucei gambiense | Tbg.972.2.4210 | glycosylphosphatidylinositol-specific phospholipase C |
Trypanosoma brucei | Tb927.2.6000 | glycosylphosphatidylinositol-specific phospholipase C |
Trypanosoma congolense | TcIL3000_2_1660 | glycosylphosphatidylinositol-specific phospholipase C |
Trypanosoma cruzi | TcCLB.508765.30 | VSG lipase |
Trypanosoma cruzi | TcCLB.506821.30 | glycosylphosphatidylinositol-specific phospholipase C |
Trypanosoma cruzi | TcCLB.508807.5 | VSG lipase |
Trypanosoma cruzi | TcCLB.508233.50 | vsglipase, putative |
Trypanosoma cruzi | TcCLB.506617.70 | glycosylphosphatidylinositol-specific phospholipase C |
Trypanosoma cruzi | TcCLB.507041.120 | variant-surface-glycoprotein phospholipase C, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.2.6000 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.6000 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.6000 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.2.6000 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | single cell organism (CARO:0000064) | bloodstream stage (PLO:0040) | inferred from bioassay (ECO:0000094) | Trypanosoma brucei brucei | No drug identifiers listed for this gene. |
Annotator: | ts4@sanger.ac.uk. | Comment: | Drug: glucosaminylinsitol derivatives. . | References: | 7852313 | |
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | single cell organism (CARO:0000064) | epimastigote (BTO:0000409) | inferred from bioassay (ECO:0000094) | Trypanosoma brucei brucei | No drug identifiers listed for this gene. |
Annotator: | ts4@sanger.ac.uk. | Comment: | Drug: glucosaminylinsitol derivatives. . | References: | 7852313 | |
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | ts4@sanger.ac.uk. | Comment: | Drug: glucosaminylinsitol derivatives. . | References: | 7852313 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Target | Type | Source | Notes |
---|---|---|---|
Tb927.2.6000 | purified protein | BRENDA | A protein with this EC number or name or sequence has been purified from Trypanosoma brucei ( 4 ) |
3 literature references were collected for this gene.